Cardiology · 1987
FDA approval of lovastatin, the first statin (HMG-CoA reductase inhibitor)
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
Through the 1970s and early 1980s, clinicians had few effective tools for lowering LDL cholesterol. Bile acid sequestrants like cholestyramine could reduce LDL by 15-20%, but their tolerability was poor. Niacin lowered lipids but carried substantial flushing and hepatotoxicity. The coronary risk associated with elevated LDL had been established by epidemiological data, including Framingham and the MRFIT study, but translating that knowledge into durable lipid reduction in daily clinical practice remained difficult.
The pharmacological answer came from an unexpected source: fungal metabolism. Akira Endo, a biochemist at Sankyo Pharmaceuticals in Tokyo, began systematically screening fungal metabolites in 1971, reasoning that organisms competing for cholesterol-rich environments might have evolved inhibitors of cholesterol synthesis. He identified compactin from Penicillium citrinum in 1973 as a potent inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway. Independently, researchers at Merck, led by research chief P. Roy Vagelos, isolated a related compound, lovastatin, from Aspergillus terreus. Merck pursued clinical development, and on August 31, 1987, the FDA cleared lovastatin as the first approved drug in the statin class.
Early clinical data showed lovastatin reduced LDL cholesterol by 25-45%, a larger effect than any previously available agent. The drug's mechanism was clean: competitive inhibition of HMG-CoA reductase reduced hepatic cholesterol synthesis, which upregulated LDL receptor expression and increased clearance of LDL particles from plasma. Despite the lipid-lowering potency, the mortality question remained unanswered at the time of approval, as the FDA accepted surrogate endpoints for the initial indication.
The mortality evidence came in stages over the following decade. The Scandinavian Simvastatin Survival Study (4S) in 1994 showed that simvastatin reduced coronary death and total mortality in patients with established coronary disease. WOSCOPS in 1995 extended the benefit to primary prevention in men with hypercholesterolemia. These trials used second-generation statins, but they confirmed the mechanistic principle established by lovastatin. By the late 1990s, statin therapy had become standard of care for secondary prevention and for high-risk primary prevention.
By the 2010s, statins had become one of the most widely prescribed drug classes in pharmaceutical history, with use extending to hundreds of millions of patients globally. Lovastatin itself was eventually superseded by more potent agents, including atorvastatin and rosuvastatin, but the compound's approval in 1987 opened the clinical and commercial path for the entire class. Endo, who had identified the foundational chemistry years before Merck's development program, received belated recognition through numerous international awards, including the Lasker-DeBakey Clinical Medical Research Award in 2008.
Key People
- Akira Endo — Japanese biochemist who discovered HMG-CoA reductase inhibition from fungi
- P. Roy Vagelos — Merck research chief who led lovastatin's clinical development and FDA approval
- Michael Brown — UT Southwestern biochemist; LDL receptor work provided the mechanistic rationale
- Joseph Goldstein — Co-discoverer of LDL receptor biology; Nobel Prize 1985 with Brown
Proc Jpn Acad Ser B Phys Biol Sci, 2010
Related landmarks
- 1987 · CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study) (Cardiology)
- 1986 · GISSI-1 (Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction) (Cardiology)
- 1988 · ISIS-2 (Second International Study of Infarct Survival) (Cardiology)
- 1991 · SOLVD Treatment Trial (Cardiology)